A Phase II Study of Lapatinib in Combination With Trastuzumab in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2013
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 25 Sep 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 17 Aug 2012 Planned End Date changed from 1 Dec 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.